Home › Peripheral T-Cell Lymphoma › Massachusetts › Boston
Peripheral T-Cell Lymphoma clinical trials in Boston, MA
5 studies for Peripheral T-Cell Lymphoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- Beth Israel Deaconess Medical Center - Research, Boston
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- Massachusetts General Hospital, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecruitingPhase 1/2
- Research Site, Boston
- Research Site, Boston
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Recruiting
- Dana Farber Cancer Institute, Boston
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RecruitingPhase 2
- Dana Farber Cancer Institute, Boston
Peripheral T-Cell Lymphoma trials in other cities
- Houston, TX9 studies
- New York City, NY6 studies
- Baldwin Park, CA5 studies
- Philadelphia, PA4 studies
- Atlanta, GA3 studies
- Aurora, CO3 studies
- Columbus, OH3 studies
- Ann Arbor, MI3 studies
Other studies in Boston
- Breast Cancer110 studies
- Non-Small Cell Lung Cancer89 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer60 studies
- Depression51 studies
- Endometrial Cancer50 studies
- Acute Myeloid Leukemia45 studies
- Pancreatic Cancer44 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.